CYBN) Transferring Quickly to Progress CYB003 Towards Medical Improvement

Get instant notifications when there is news about your stocks. Request your one-week free trial of StreetInsider Premium here.

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on advancing Psychedelics to Therapeutics (TM), has a confirmed scientific advisory meeting with the UK Medical and Healthcare Products Regulatory Agency (MHRA “) for . announced in the first quarter of calendar year 2022. According to the update, this program milestone will bring Cybin closer to the advancement of its lead investigational candidate CYB003 into clinical development for the treatment of major depressive disorder (“MDD”) and alcohol use disorder (“AUD”). . “Encouraged by positive preclinical results demonstrating the benefits of our novel deuterated psilocybin analog over oral psilocybin for the treatment of mental health, we are moving rapidly to bring CYB003 into clinical development,” said Doug Drysdale, CEO of Cybin. “We look forward to working with the MHRA to determine the next steps for our clinical development path to evaluate CYB003 for the treatment of MDD and AUD in the UK.”

To view the full press release, visit

About Cybin Inc.

Cybin is a leading ethical biopharmaceutical company that works with a network of world-class partners and internationally recognized scientists to develop safe and effective therapeutics for patients to treat a wide variety of mental health problems. Headquartered in Canada, Cybin was founded in 2019 and operates in the United States, United Kingdom and Ireland. The company is focused on advancing psychedelics to therapeutics (TM) through the development of proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental disorders. For more information, please visit the company’s website at

NOTE TO INVESTORS: For the latest news and updates on CYBN, please visit the company’s newsroom at

Via PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialist content distribution company that aggregates and disseminates (1) news and information on the latest developments in all aspects and advances in psychedelics and their use, (2) creates PsychedelicNewsBreaks to quickly alert investors to important industry news , (3) utilizes a team of seasoned editors to improve press releases for maximum impact, (4) helps companies manage and optimize social media across a range of platforms, and (5) provides unparalleled corporate communications solutions. PNW stays up to date with the latest information and has built a reputation for being the one stop shop for reporting on psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record in helping both public and private companies gain a foothold with a broad audience of investors, consumers, the media and the general public by using our extensive distribution network of more than 5,000 major syndication agencies uses. PNW is committed to providing improved visibility and brand awareness to companies operating in the emerging psychedelic markets.

For instant SMS notifications, text “Groovy” to 21000 (US phones only).

For more information, please visit

Please see the full terms of use and disclaimers on the PsychedelicNewsWire website that apply to all content provided by PNW, regardless of where it is published or republished:

Do you have any questions or are you interested in working with PNW? Ask our editor

PsychedelicNewsWire (PNW)
San Francisco, California
415.949.5050 office

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button